Lumos Diagnostics Holdings Ltd.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lumos Diagnostics Holdings Limited (ASX:LDX, OTC:LDXHF) develops, manufactures, and commercializes point-of-care diagnostic products and services focused on infectious and inflammatory diseases for healthcare professionals in the United States, Australia, and select international markets. Founded in 2018 and headquartered in Carlsbad, California, with additional facilities in Sarasota, Florida, and South Melbourne, Australia, the company offers proprietary Lumos-branded tests including FebriDx, a fingerstick blood test that differentiates bacterial from viral respiratory infections; ViraDx, a three-in-one point-of-care test detecting influenza A, influenza B, and COVID-19; and CoviDx, a COVID-19 antigen test; alongside disposable and hand-held digital readers such as Lumos Leelu. It provides comprehensive services encompassing customized assay development, reader platform integration, clinical validation, cloud data analytics, and commercial-scale manufacturing of point-of-care tests. Recent developments include a landmark US$317 million exclusive US distribution agreement for FebriDx with PHASE Scientific in 2025; a strategic collaboration with AcuityMD to enhance US market access and reimbursement visibility; a follow-on contract with Aptatek Biosciences to advance the PheCheck in-home monitoring device for phenylketonuria; US$6.2 million non-dilutive funding from BARDA for a FebriDx pediatric CLIA-waiver study, which commenced enrollment; a new distribution agreement with Amtech of the YesGroup alliance; expanded Medicare reimbursement coverage from additional administrative contractors; and a A$5.0 million secured loan facility from major shareholders Tenmile and Ryder Capital.
Dow Jones closes above 52,000 for the first time as US-Iran truce holds
Lumos Diagnostics receives A$710,000 R&D tax rebate to support point-of-care technology development
Lumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. Transcript
US commercialisation of FebriDx® to be discussed at Lumos Webinar: Thursday, June 11, at 10:30am AEST
Five Below shares fall as tariff assumptions draw focus from earnings beat
FTSE 100 Live: Stocks vacillating, CMC surges, SpaceX to IPO next week
Lumos sees strong early reimbursement signals as FebriDx® rollout gains traction in US urgent care market
Small Cap Watch: Small Caps mixed as Elixir, Ora Banda, Lumos and Scorpion deliver key updates
Lumos hits major US regulatory milestone with FebriDx study support
Nasdaq set to lead the charge higher as Wall Street looks to jobs report
AppLovin tops Q1 earnings expectations on AI-driven ad growth
Boeing continues to show turnaround progress, keeping Banking of America bullish
Lumos Diagnostics raises $265,000 through share purchase plan as FebriDx rollout gathers pace
Lumos Diagnostics Holdings Limited (LDXHF) Q3 2026 Earnings Call Transcript
Agnico Eagle to buy Rupert, Aurion in $3B Finland consolidation drive
Lumos pivots to commercial growth phase following FebriDx breakthrough
Cleveland Cliffs shares fall as higher costs overshadow Q1 earnings beat
FTSE 100 Live: Shares mixed as Iran talks awaited, Ceres and Rank jump
Nasdaq and Dow Jones set for flat start as Trump hails 'amazing' Iran talks in two days
Lumos Diagnostics expands WellStreet rollout to 43 sites as FebriDx gains US traction